Pharmacology and placental transfer of a human αv integrin monoclonal antibody in rabbits

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 89, Issue 2, 2010, Pages 116-123

  Martin, Pauline L ^a   Zhou, Zhao ^b   Van Den Bulck, Kathleen ^c   Kwok, Deborah ^a   Powers, Gordon ^a   Jiao, Qun ^a   Schantz, Allen ^a   Treacy, George ^a  

^a CENTOCOR INC   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

v integrin; Embryofetal development; Monoclonal antibody; Placental transfer; Rabbit

Indexed keywords

INTETUMUMAB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN;

AMNION FLUID; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; AUTOPSY; CELL ADHESION; CONTROLLED STUDY; DRUG BLOOD LEVEL; EMBRYO DEVELOPMENT; FEASIBILITY STUDY; FETUS DEVELOPMENT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MATERNAL BLOOD; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; RABBIT;

AMNIOTIC FLUID; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AORTA, THORACIC; BLOOD VESSELS; CELL ADHESION; CELLS, CULTURED; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; ENDOTHELIAL CELLS; FEMALE; FETAL DEVELOPMENT; FETUS; INJECTIONS, INTRAVENOUS; INTEGRIN ALPHA5; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; NEOVASCULARIZATION, PHYSIOLOGIC; PLACENTA; PREGNANCY; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 77951748828     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20232     Document Type: Article

References (32)

1. Avastint™ (bevacizumab). 2004. United States, Food and Drug Administration, drug approval report, pharmacology review, www.drugs@fda.gov
2. Avastint™ (bevacizumab). 2005. European Medicines Agency, European Public Assessment Report, www.emea.europa.eu
3. Apparao KBC, Murray MJ, Fritz MA, Meyer WR, Chambers AF, Truong PR, Lessey BA. 2001. Osteopontin and its receptor αvβ3 are coexpressed in the human endometrium during the menstrual cycle but down regulated differentially. J Clin Endocrinol Metab 86: 4991-5000.
4. Bader BL, Rayburn H, Crowley D, Hynes RO. 1998. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95:507-519. (Pubitemid 28533307)
5. Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, Sharp C, Shahied-Arruda L, Doshi P, Nakada MT, Anderson GM. 2008. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metast 25:139-148.
6. Dancis J, Lind J, Oratz M, Smolens J, Vara P. 1961. Placental transfer of proteins in human gestation. Am J Obstet Gyncol 82:167-171.
7. Eskens FALM, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT. 2003. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins avb3 and avb5 in patients with advanced solid tumours. Eur J Cancer 39:917-926. (Pubitemid 36428623)
8. Illera MJ, Lorenzo PL, Gui Y-T, Beyler SA, Apparao KBC, Lessey BA. 2003. A role for αvβ3 integrin during implantation in the rabbit model. Biol Reprod 68:766-771.
9. Jauniaux E, Gulbis B. 2000. In vivo investigation of placental transfer early in human pregnancy. Eur J Obstet Gynecol 92:45-49.
10. Lessey BA, Damjanovich L, Coutifaris C, Castelbaum A, Albelda SM, Buck CA. 1992. Integrin adhesion molecules in the human endometrium. J Clin Invest 90:188-195.
11. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. 1996. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J Reprod Immunol 36:248-255. (Pubitemid 26383975)
12. Martin PL, Jiao Q, Cornacoff J, Hall W, Saville B, Nemeth JA, Schantz A, Mata M, Jang H, Fasanmade AA, Anderson L, Graham MA, Davis HM, Treacy G. 2005. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res 11:6959-6965. (Pubitemid 41428754)
13. Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. 2007. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128-2135. (Pubitemid 46649882)
14. Miettinen PJ, Berger JE, Menses J, Phung Y, Pedersen RA, Werb ZR. 1995. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-341.
15. Nexavar™ (sorafenib). 2005. United States, Food and Drug Administration, drug approval report, pharmacology review, www.drugs@fda.gov
16. Nexavar™ (sorafenib). 2006. European Medicines Agency, European Public Assessment Report, www.emea.europa.eu
17. Nicosia RF, Ottinetti A. 1990. Growth of microvessels in serum-free matrix culture of rat aorta. Lab Invest 63:115-122.
18. Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. 2008. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Therapeut 7: 1569-1578.
19. Palfi M, Selbring A. 1998. Placental transport of maternal immunoglobulin G. Am J Reprod Immunol 39:24-26.
20. Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D. 2009. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Def Res B 86:204-213.
21. Pentsuk N, van der Laan JW. 2009. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Def Res 86:328-344.
22. Rodolfo A. 1934. A study of the permeability of the placenta of the rabbit to antibodies. J Exp Zool 68:215-235.
23. Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O'Neill CA. 1999 Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78-86. (Pubitemid 29075749)
24. Simister NE. 2003. Placental transport of immunoglobulin G. Vaccine 21:3365-3369.
25. Smith JW, Vestal DJ, Irwin SV, Burke TA, Cheresh DA. 1990. Purification and functional characterization of integrin αvβ5. J Biol Chem 265:11008-11013.
26. Sutent™ (sunitinib). 2006. United States, Food and Drug Administration, drug approval report, pharmacology review, www.drugs@fda.gov
27. Sutent™ (sunitinib). 2006. European Medicines Agency, European Public Assessment Report, www.emea.europa.eu
28. Sueoka K, Kuji N, Shokawa S, Tanaka M, Miyazaki T, Yoshimura Y. 1997. Integrins and reproductive physiology: expression and modulation in fertilization, embryogenesis, and implantation. Fertil Steril 67:799-811. (Pubitemid 27183905)
29. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT. 2004. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110:326-335. (Pubitemid 38649882)
30. Verdier F, Barror PC, Burge J. 2003. Reproductive toxicity testing of vaccines. Toxicology 185:213-219.
31. Vinatier D. 1995. Integrins and reproduction. Eur J Obstet Gynecol Reprod Biol 59:71-81.
32. Zuch CL, Bricarello A, Beyer JC, Thonford PJ, Christian BJ, Hoberman AM. 2005. Reproductive and developmental effects of Avastin™, a monoclonal antibody against vascular endothelial growth factor. Toxicol (abstract) 804.